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Table 1. Results of Intravenous Adenosine Protocol: I
Regional Myocardial Blood Flow
(rnl-rnm- " g - I. mean ± I standard deviation)
(n = 8)
the results of our study and those of others. The Discussion section
of our report provides several possible reasons for these differences.
We began these studies of adenosine and myocardial blood
flow with an intravenous design (a technique commonly employed
in our laboratory), as suggested by Gould, but had to abandon this
approach because relative systemic hypotension induced by aden-
Distal zone
Endo 1.69 ± 0.30 2.50 ± 0.71* 2.11 ± 0.36
Epi 1.55 ± 0.37 2.29 ± 0.51* 1.91 ± 0.37
Trans 1.61 ± 0.33 2.39 ± 0.60* 2.01 ± 0.35
Circumflex zone
Endo 1.70 ± 0.36 2.56 ± 0.75* 2.19±041
Epi 1.59 ± 039 2.45 ± 0.70* 2.00 ± 0.45
Trans 1.64 ± 0.37 25 ± 0.73* 2.09 ± 043
Distal:LCx ratio
Endo 1.00 ± 0.05 0.98 ± 0.07 0.97 ± 0.07
Epi 0.98 ± 0.07 096 ± 0.11 0.96 ± 0.07
Trans 0.99 ± 0.05 0.97 ± 0.08 0.97 ± 0.05
Endo:Epi ratio
Distal zone 1.I1±012 1.08 ± 009 1.11 ± 0.11
LCx zone 1.08 ± 0.07 104 ± 0.03 1.10 ± 0.05
osine (3.5 to 7.0 mg/min) limited the magnitude of flow increases
in both stenosis and nonstenosis zones, thereby making it difficult
to adequately challenge the vasodilatory reserve of the stenosis
zone (results of pilot study attached-Tables I and 2). Data ac-
quired, however, showed no difference in regional flow when
portions of the same hearts were compared with and without a
stenosis during adenosine infusion.
Finally, it is worth noting 1) we never once mentioned the word
"Imaging" in our report, nor did we in any way imply that our
experimental methods could or should be used in conjunction with
myocardial imaging for the assessment of the physiologic Signifi-
cance of coronary stenoses in humans, and 2) the possibility that
arteriolar resistance in the 50% stenosis group was reduced in com-
parison with that of the nonstenosis group was specifically rec-
ognized in the Discussion section of our paper. The latter obser-
vation does not alter the fact that maximal flows attained in response
to adenosine were comparable in both groups.
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Control 2AdenosineControl I
*p < 0.05 versus control I; Endo = endocardium; Epi = epicardium:
LCx = left Circumflex; Trans = transmural
Note: I) Distal zone refers to myocardium distal to a fixed. rigid. 7
mm long, 50% stenosis 2) Circumflex zone refers to myocardium perfused
by the unobstructed circumflex coronary artery of each arumal. 3) Failure
of all distal:LCx flow ranos to change significantly versus control I in
response to adenosine. 4) Failure of the endo:epi flow ratio In both distal
and circumflex zones to change Significantly versus control I In response
to adenosine.
Table 2. Results of Intravenous Adenosine Protocol: II
Correction
It has come to our attention that one of the regression equations
in Table 3 of our article (I) was incorrect. The systolic equation
"Q-peak rate of emptying (LV) x 100 = - 0.10 HR + 25"
should read "Q-peak rate of emptying (LV) x 100 = - 0.10 HR
+ 29." Regrettably this typographical error was not detected until
after the manuscript was published.
Hemodynamics (mean ± I standard deviation)
(n = 8)
Control I Adenosine Control 2
Heart rate 100 ± 18 108 ± 18 105 ± IS
(min -I)
Mean aortic 1220 ± 11.2 97.0 ± 10.0* 124.0 ± 152
pressure (rnm Hg)
Mean left atrial 4.6 ± 3.6 4.2 ± 36 4.8 ± 3.7
pressure (mm Hg)
Mean distal coronary 117 0 ± 12.2 89.4 ± 11.9* 119.0 ± 149
pressure (mm Hg)
*p < 0.0 I versus control I.
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